CN107467667B - 一种含有两种不饱和脂肪酸和唾液酸的复方制剂 - Google Patents
一种含有两种不饱和脂肪酸和唾液酸的复方制剂 Download PDFInfo
- Publication number
- CN107467667B CN107467667B CN201710582418.1A CN201710582418A CN107467667B CN 107467667 B CN107467667 B CN 107467667B CN 201710582418 A CN201710582418 A CN 201710582418A CN 107467667 B CN107467667 B CN 107467667B
- Authority
- CN
- China
- Prior art keywords
- compound preparation
- sialic acid
- types
- acid
- ara
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 106
- 150000001875 compounds Chemical class 0.000 title claims abstract description 88
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title claims abstract description 62
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title claims abstract description 62
- 239000002253 acid Substances 0.000 title claims abstract description 33
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 24
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960001231 choline Drugs 0.000 claims abstract description 24
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000000463 material Substances 0.000 claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 10
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 10
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 7
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 21
- 235000013793 astaxanthin Nutrition 0.000 claims description 21
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 21
- 229940022405 astaxanthin Drugs 0.000 claims description 21
- 239000001168 astaxanthin Substances 0.000 claims description 21
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 235000010445 lecithin Nutrition 0.000 claims description 16
- 229940067606 lecithin Drugs 0.000 claims description 16
- 239000000787 lecithin Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 14
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 235000013871 bee wax Nutrition 0.000 claims description 8
- 239000012166 beeswax Substances 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 7
- 229960003080 taurine Drugs 0.000 claims description 7
- 229940050168 zinc lactate Drugs 0.000 claims description 7
- 235000000193 zinc lactate Nutrition 0.000 claims description 7
- 239000011576 zinc lactate Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 abstract description 20
- 235000016709 nutrition Nutrition 0.000 abstract description 19
- 230000002028 premature Effects 0.000 abstract description 17
- 230000035764 nutrition Effects 0.000 abstract description 15
- 230000018109 developmental process Effects 0.000 abstract description 13
- 235000020256 human milk Nutrition 0.000 abstract description 10
- 210000004251 human milk Anatomy 0.000 abstract description 10
- 230000004641 brain development Effects 0.000 abstract description 8
- 239000013589 supplement Substances 0.000 abstract description 6
- 230000007547 defect Effects 0.000 abstract description 4
- 230000008131 children development Effects 0.000 abstract description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 35
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 35
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 35
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 35
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 34
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 33
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 17
- 239000003513 alkali Substances 0.000 description 11
- 235000013372 meat Nutrition 0.000 description 11
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 6
- 229960004203 carnitine Drugs 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000001202 rhombencephalon Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010020466 Hunger Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000015015 brainstem development Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种含有两种不饱和脂肪酸和唾液酸的复方制剂,涉及一种婴儿发育的复方制剂,以重量百分比计,复方制剂包括5%~15%DHA,10%~20%ARA,2%~8%唾液酸,2%~5%磷脂酰丝氨酸、1%~2%抗氧化剂、1%~3%乙酰左旋肉碱、1%~2%胆碱和辅料。与现有技术相比,本发明提出了一种复方制剂,主要为早产儿以及母乳不足的初生儿补充大脑发育的必要元素,保证婴儿大脑正常发育,避免因为营养确实造成的脑部缺陷。
Description
技术领域
涉及一种婴儿发育的复方制剂,尤其是一种婴儿脑部发育的复方制剂。
背景技术
二十二碳六烯酸,即DHA,是含有22个碳原子和6个双键的直链脂肪酸,是人体所必需的一种多不饱和脂肪酸,但生成量较低,主要通过食物补充。DHA是大脑细胞膜的重要构成成分,参与脑细胞的形成和发育,对神经细胞轴突的延伸和新突起的形成有重要作用,可维持神经细胞的正常生理活动,促进神经细胞蛋白质合成,参与大脑思维和记忆形成过程。花生四烯酸,学名二十碳四烯酸,既ARA,含有四个碳-碳双键,一个碳-氧双键,为高级不饱和脂肪酸。广泛分布于动物界,人体内可由亚油酸合成。在幼儿时期ARA属于必需脂肪酸。但是在婴幼儿期,宝贝体内合成ARA的能力较低,因此对于正处于体格发育黄金期的宝贝来说,在食物中提供一定的ARA,会更有利于其体格的发育。ARA的缺乏对于人体组织器官的发育,尤其是大脑和神经***发育可能产生严重不良影响。唾液酸在大脑和神经***的产生和发育中发挥非常重要的作用。足够的唾液酸供应对于低出生体重儿童脑功能的正常发育尤其重要。婴儿出生后,母乳中的唾液酸含量可以保证他们的正常发育,但是分娩后母亲体内唾液酸水平随着时间的推移成下降趋势。因此,在孕期及孕后持续摄入足量唾液酸,可以帮助维持体内的唾液酸水平。不仅如此,唾液酸的含量还与DHA的含量有着明显的相关性,这表明它极有可能与婴儿的脑结构和脑功能发育有关,可能两者都对早期脑发育有益。
对于早产儿以及初生婴儿来说,他们身体还未发育完全,体内无法合成DHA、ARA和,唾液酸完全依靠母乳进行补养,如果无法补充DHA、ARA和唾液酸则会对大脑神经的发育造成恶劣的影响。但是早产儿以及部分初生婴儿的母亲母乳量并不充足,这是就需要通过其他手段进行营养物质的补充。
发明内容
本发明针对现有技术中的不足,提供了一种含有两种不饱和脂肪酸和唾液酸的复方制剂,主要为早产儿以及母乳不足的初生儿补充大脑发育的必要元素,保证婴儿大脑正常发育,避免因为营养确实造成的脑部缺陷。
为了解决上述技术问题,本发明通过下述技术方案得以解决:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括5%~15%DHA,10%~20%ARA, 2%~8%唾液酸,2%~5%磷脂酰丝氨酸、1%~2%抗氧化剂、1%~3%乙酰左旋肉碱、1%~2%胆碱和辅料。
上述技术方案中,优选的,还包括1%~3%乳酸锌和1%~5%牛磺酸。
上述技术方案中,优选的,为,所述的辅料为卵磷脂、蜂蜡、明胶、甘油、水的一种或多种混合物。
上述技术方案中,优选的,所述的抗氧化剂为维生素A、维生素C、维生素E、虾青素的一种。
上述技术方案中,优选的,所述的抗氧化剂为虾青素。
上述技术方案中,优选的,当所述的辅料为卵磷脂时,复方制剂为粉状。
上述技术方案中,优选的,当所述的辅料为水时,复方制剂为水溶液。
上述技术方案中,优选的,当所述的辅料为多种混合物时,复方制剂为糊状或膏体。
上述技术方案中,优选的,以重量比计,复方制剂中DHA和ARA的含量为1:2。
上述技术方案中,优选的,以重量百分比计,复方制剂包括10%DHA,20%ARA,4%唾液酸,2.5%磷脂酰丝氨酸、1%抗氧化剂、1%乙酰左旋肉碱、1.5%胆碱和60%辅料。
DHA、ARA和唾液酸是婴儿脑部发育不可或缺的必要营养物质,这些营养物质主要由母乳提供,但是早产儿以及部分婴儿母亲的母乳不足,不能为婴儿补充充足营养,一旦DHA、 ARA和唾液酸不足就会造成婴儿脑部的缺陷,影响婴儿的一生。本复方制剂可以代替母乳中脑部发育的营养成分,根据早产儿、初生儿、3月-6月婴儿、6月-12月婴儿不同的营业摄入方式具有粉剂、水剂、糊状体、膏体等多种形式。本复方制剂的主要成分是DHA,ARA,唾液酸,磷脂酰丝氨酸、抗氧化剂、乙酰左旋肉碱、胆碱,还可以根据实际需要添加乳酸锌和牛磺酸。本复方制剂与现有营养剂最大的不同之处在于为了避免早产儿消化***不完善无法吸收而开发出粉剂和水剂,粉剂和水剂可以通过注射的方式对早产儿进行营养补充。公知的,相比成人,婴儿的血脑屏障效果较弱,一些大颗粒分子也能通过血脑屏障进入脑部,本复方制剂中的DHA,ARA,唾液酸,磷脂酰丝氨酸、乙酰左旋肉碱都是能极易通过血脑屏障的物质,抗氧化剂也可以选择能通过血脑屏障的虾青素,早产儿和新生儿的脑部从血液中汲取胆碱的能力是极强的,通过静脉注射可以直接让这些营养元素迅速作用到脑部,促进脑部发育,这样避免了早产儿或部分新生儿消化***不完善或具有消化***疾病无法吸收营养物质的问题。对于3月-6月的婴儿,可以通过进食进行补充,这阶段的婴儿已经可以稳定的摄入食物,没有特殊要求无需大剂量的补充脑部营养物,此时可以通过水剂和糊状体为于3 月-6月的婴儿补充适量营养素。对6月-12月婴儿的可以通过糊状体和膏体进食,此时复方制剂还可以加入乳酸锌和牛磺酸,进行更全面的补充。因为DHA、ARA、牛磺酸、锌同时补充可以更好的促进大脑发育,同时本复方制剂中DHA和ARA比例为1:2,在这个比例婴儿对DHA和ARA的吸收更加彻底,对大脑发育促进作用更明显。
与现有技术相比,本发明提出了一种复方制剂,主要为早产儿以及母乳不足的初生儿补充大脑发育的必要元素,保证婴儿大脑正常发育,避免因为营养确实造成的脑部缺陷。
具体实施方式
为使本发明的目的、技术方案及优点更加清楚明白,对本发明进一步详细说明。
实施例1:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括5%DHA,10%ARA,2%唾液酸,2%磷脂酰丝氨酸、1%虾青素、1%乙酰左旋肉碱、1%胆碱和78%卵磷脂。本实施例的复方制剂为粉剂。
实施例2:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括7%DHA,14%ARA,3%唾液酸,3%磷脂酰丝氨酸、1.5%虾青素、1.5%乙酰左旋肉碱、2%胆碱和68%卵磷脂。本实施例的复方制剂为粉剂。
实施例3:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括10%DHA,20%ARA,2%唾液酸,3%磷脂酰丝氨酸、2%虾青素、1%乙酰左旋肉碱、2%胆碱和60%卵磷脂。本实施例的复方制剂为粉剂。
实施例4:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括10%DHA,20%ARA,8%唾液酸,5%磷脂酰丝氨酸、2%维生素A、3%乙酰左旋肉碱、2%胆碱和50%卵磷脂。本实施例的复方制剂为粉剂。
实施例5:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括7%DHA,14%ARA,4%唾液酸,2.5%磷脂酰丝氨酸、1.5%虾青素、2%乙酰左旋肉碱、1%胆碱和68%卵磷脂。本实施例的复方制剂为粉剂。
实施例6:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括10%DHA,20%ARA,4%唾液酸,2.5%磷脂酰丝氨酸、1%虾青素、1%乙酰左旋肉碱、1.5%胆碱和60%卵磷脂。本实施例的复方制剂为粉剂。
实施例7:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括5%DHA,10%ARA,2%唾液酸,2%磷脂酰丝氨酸、1%虾青素、1%乙酰左旋肉碱、1%胆碱和78%水。本实施例的复方制剂为水剂。
实施例8:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括7%DHA,14%ARA,3%唾液酸,3%磷脂酰丝氨酸、1.5%虾青素、1.5%乙酰左旋肉碱、2%胆碱和68%水。本实施例的复方制剂为水剂。
实施例9:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括10%DHA,20%ARA,2%唾液酸,3%磷脂酰丝氨酸、2%虾青素、1%乙酰左旋肉碱、2%胆碱和60%水。本实施例的复方制剂为水剂。
实施例10:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括10%DHA,20%ARA,8%唾液酸,5%磷脂酰丝氨酸、2%维生素A、3%乙酰左旋肉碱、2%胆碱和50%水。本实施例的复方制剂为水剂。
实施例11:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括7%DHA,14%ARA,4%唾液酸,2.5%磷脂酰丝氨酸、1.5%虾青素、2%乙酰左旋肉碱、1%胆碱和68%水。本实施例的复方制剂为水剂。
实施例12:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括10%DHA,20%ARA,4%唾液酸,2.5%磷脂酰丝氨酸、1%虾青素、1%乙酰左旋肉碱、1.5%胆碱和60%水。本实施例的复方制剂为水剂。
实施例13:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括10%DHA,20%ARA,2%唾液酸,3%磷脂酰丝氨酸、2%虾青素、1%乙酰左旋肉碱、2%胆碱和20%卵磷脂、10%蜂蜡、10%甘油、20%水。本实施例的复方制剂为糊体。
实施例14:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括10%DHA,20%ARA,8%唾液酸,5%磷脂酰丝氨酸、2%虾青素、3%乙酰左旋肉碱、2%胆碱和20%卵磷脂、5%蜂蜡、5%甘油、20%水。本实施例的复方制剂为糊体。
实施例15:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括7%DHA,14%ARA,4%唾液酸,2.5%磷脂酰丝氨酸、1.5%虾青素、2%乙酰左旋肉碱、1%胆碱和20%卵磷脂、10%蜂蜡、10%甘油、26%水。本实施例的复方制剂为糊体。
实施例16:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括10%DHA,20%ARA,2%唾液酸,3%磷脂酰丝氨酸、2%虾青素、1%乙酰左旋肉碱、2%胆碱、1%乳酸锌、1%牛磺酸和10%卵磷脂、10%蜂蜡、8%明胶、10%甘油、 20%水。本实施例的复方制剂为膏体。
实施例17:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括10%DHA,20%ARA,8%唾液酸,5%磷脂酰丝氨酸、2%虾青素、3%乙酰左旋肉碱、2%胆碱、3%乳酸锌、5%牛磺酸和10%卵磷脂、5%蜂蜡、12%明胶、5%甘油、 10%水。本实施例的复方制剂为膏体。
实施例18:一种含有两种不饱和脂肪酸和唾液酸的复方制剂,以重量百分比计,复方制剂包括7%DHA,14%ARA,4%唾液酸,2.5%磷脂酰丝氨酸、1.5%虾青素、2%乙酰左旋肉碱、1%胆碱、2%乳酸锌、3%牛磺酸和10%卵磷脂、10%蜂蜡、11%明胶、10%甘油、20%水。本实施例的复方制剂为膏体。
实施例 | 早产儿 | 人数 | 平均每日摄入量 | 摄入天数 | 摄入结束后平均时脑容量 |
实施例1 | 34周 | 1 | 2ml | 45 | 376g |
实施例2 | 34周 | 1 | 2ml | 45 | 382g |
实施例3 | 35周 | 1 | 2ml | 40 | 387g |
实施例4 | 35周 | 1 | 2ml | 40 | 386g |
实施例5 | 36周 | 1 | 2ml | 35 | 386g |
实施例6 | 36周 | 1 | 2ml | 35 | 382g |
表1-早产儿服用本复方制剂实施例1至6足月后脑容量表
在表1中早产儿为非母乳喂养,本复方制剂并非早产儿唯一营养摄入手段,而是与其他营养物共同摄入,本复方制剂主要为新生儿脑发育提供营养。其中在早产儿消化***未发育完全前通过静脉注射,能进食后通过进食摄入。静脉注射和进食摄入都需要通过其他溶剂对本复方制剂粉剂或者水剂进行溶解。
表2-新生儿服用本复方制剂实施例7至12 6个月后脑容量表
在表2中新生儿为非母乳喂养,本复方制剂并非新生儿唯一营养摄入手段,而是与其他营养物共同摄入,本复方制剂主要为新生儿脑发育提供营养。在表2中都通过进食进行营养的摄入。进食摄入都需要通过其他溶剂对本复方制剂糊状或者水剂进行溶解。
实施例 | 人数 | 平均每日摄入量 | 摄入天数 | 摄入结束后平均时脑容量 |
实施例16 | 2 | 5ml | 180 | 995g |
实施例17 | 3 | 5ml | 180 | 977g |
实施例18 | 2 | 5ml | 180 | 982g |
表3-6个月婴儿服用本复方制剂实施例16至18 6个月后脑容量表
在表3中6个月婴儿为非母乳喂养,本复方制剂并非6个月婴儿唯一营养摄入手段,而是与其他营养物共同摄入,本复方制剂主要为6个月婴儿脑发育提供营养。在表3中都通过进食进行营养的摄入。进食摄入都需要通过其他溶剂对本复方制剂水剂进行溶解,糊状或者膏状可以直接进食或者溶解后进食。
在表1至表3中对大脑营业物质的供给都有本复方制剂提供,其他营养物提供其他维持生命的营养成分,大部分并不涉及脑部的发育。由表1至3可得,本复方制剂可以替代母乳中的脑发育成分,摄入本复方制剂能让大脑发育良好,脑容量复合婴儿各个阶段的平均标准,部分指标比平均标准高。本复方制剂摄入方式多样,安全无副作用,在母亲母乳不足以及其他情况下可以为早产儿至1周岁阶段的婴儿提供可靠的脑部营养。
在表1至表3中的脑容量都是通过X光或者脑CT估算,所有被测儿童均无缺陷,生长环境良好。
Claims (8)
1.一种含有两种不饱和脂肪酸和唾液酸的复方制剂,其特征为,以重量百分比计,复方制剂由5%~15%DHA,10%~20%ARA,2%~8%唾液酸,2%~5%磷脂酰丝氨酸、1%~2%抗氧化剂、1%~3%乙酰左旋肉碱、1%~2%胆碱、1%~3%乳酸锌、1%~5%牛磺酸和辅料组成。
2.根据权利要求1所述的一种含有两种不饱和脂肪酸和唾液酸的复方制剂,其特征为,所述的辅料为卵磷脂、蜂蜡、明胶、甘油、水的一种或多种混合物。
3.根据权利要求1所述的一种含有两种不饱和脂肪酸和唾液酸的复方制剂,其特征为,所述的抗氧化剂为维生素A、维生素C、维生素E、虾青素的一种。
4.根据权利要求1所述的一种含有两种不饱和脂肪酸和唾液酸的复方制剂,其特征为,所述的抗氧化剂为虾青素。
5.根据权利要求2所述的一种含有两种不饱和脂肪酸和唾液酸的复方制剂,其特征为,当所述的辅料为卵磷脂时,复方制剂为粉状。
6.根据权利要求2所述的一种含有两种不饱和脂肪酸和唾液酸的复方制剂,其特征为,当所述的辅料为水时,复方制剂为水溶液。
7.根据权利要求2所述的一种含有两种不饱和脂肪酸和唾液酸的复方制剂,其特征为,当所述的辅料为多种混合物时,复方制剂为糊状或膏体。
8.根据权利要求1所述的一种含有两种不饱和脂肪酸和唾液酸的复方制剂,其特征为,以重量比计,复方制剂中DHA和ARA的含量为1:2。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710582418.1A CN107467667B (zh) | 2017-07-17 | 2017-07-17 | 一种含有两种不饱和脂肪酸和唾液酸的复方制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710582418.1A CN107467667B (zh) | 2017-07-17 | 2017-07-17 | 一种含有两种不饱和脂肪酸和唾液酸的复方制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107467667A CN107467667A (zh) | 2017-12-15 |
CN107467667B true CN107467667B (zh) | 2018-06-26 |
Family
ID=60595127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710582418.1A Active CN107467667B (zh) | 2017-07-17 | 2017-07-17 | 一种含有两种不饱和脂肪酸和唾液酸的复方制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107467667B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108651996A (zh) * | 2018-03-26 | 2018-10-16 | 广东康侨药业有限公司 | 一种健脑益智营养组合物及其应用 |
CN109601980A (zh) * | 2018-11-15 | 2019-04-12 | 嘉必优生物技术(武汉)股份有限公司 | 一种含有唾液酸的pufa软胶囊及其制备方法 |
CN109601677A (zh) * | 2019-01-09 | 2019-04-12 | 广州富诺健康科技股份有限公司 | 一种唾液酸dha凝胶糖果 |
CN113813252B (zh) * | 2021-06-18 | 2023-05-09 | 南京北极光生物科技有限公司 | 一种ω-3多不饱和脂肪酸组合物及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998044917A1 (en) * | 1997-03-27 | 1998-10-15 | Bristol-Myers Squibb Company | Use of docosahexanoic acid and arachidonic acid enhancing the growth of preterm infants |
US7867541B2 (en) * | 2003-04-14 | 2011-01-11 | Mead Johnson Nutrition Company | Compositions and methods of formulation for enteral formulas containing sialic acid |
US20080003330A1 (en) * | 2006-06-30 | 2008-01-03 | Ricardo Rueda | Infant formulas for early brain development |
US8722120B2 (en) * | 2006-08-02 | 2014-05-13 | Mead Johnson Nutrition Company | Amino acid-based nutritional formulations |
EP2258218A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Toddlers |
NZ612472A (en) * | 2010-12-31 | 2015-02-27 | Abbott Lab | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
CN104968215B (zh) * | 2012-12-12 | 2018-09-11 | 罗纳德·罗斯代尔 | ω-3脂肪酸营养药组合物和优化方法 |
-
2017
- 2017-07-17 CN CN201710582418.1A patent/CN107467667B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN107467667A (zh) | 2017-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107467667B (zh) | 一种含有两种不饱和脂肪酸和唾液酸的复方制剂 | |
US8007853B2 (en) | Vitamin/mineral composition with DHA | |
DE60033233T2 (de) | Nahrungszusätze | |
US20050037065A1 (en) | Nutritional formulations | |
CN105558060A (zh) | 一种营养丰富的孕产妇妈妈奶粉及其制备方法 | |
CN102318827B (zh) | 一种促进神经***发育的营养素组合物及保健品 | |
CN102488011B (zh) | 一种含花生四烯酸的孕产妇配方奶粉及其制备方法 | |
CN102246863A (zh) | 一种适合于孕妇和产妇的植物调和油 | |
CN110547465A (zh) | 一种大脑神经营养组合物及制备方法 | |
CN105188411A (zh) | 增强dha和其它脂溶性营养物的生物利用度的方法 | |
CN104382934A (zh) | 一种孕妇多维片 | |
CN109105495A (zh) | 含有氯化胆碱和左旋肉碱的婴幼儿配方奶粉及其制备方法 | |
CN103191092B (zh) | 一种具有补钙和补锌作用的药物组合物 | |
TW200810762A (en) | Use of DNA and ARA in the preparation of a composition for the prevention or treatment of anemia | |
CN114271335A (zh) | 乳制品及其制备方法 | |
CN107467673B (zh) | 一种含有三种不饱和脂肪酸和锌的复方制剂 | |
CN107519198A (zh) | 一种右旋糖酐铁注射液及其制备方法 | |
CA3182980A1 (en) | Soft gelatin capsules | |
CN107789444A (zh) | 一种宠物犬亮毛维生素软胶囊组方及其制备方法 | |
WO2021190988A1 (en) | Prenatal confectionery | |
RU2311038C2 (ru) | Продукт энтерального питания "нутриэн нефро" | |
CN108851058A (zh) | 一种富含α-亚麻酸的多种维生素矿物质软胶囊及其制备方法 | |
Bainbridge et al. | Optimal nutrition in low birth weight infants | |
RU2440767C1 (ru) | Стерилизованный молочный продукт на основе козьего молока для питания беременных и кормящих женщин | |
CN107773575A (zh) | 一种宠物犬补钙软胶囊组方及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230419 Address after: Room 711, Zone C, 2nd Floor, Zhongguancun Dongsheng Science and Technology Park, No.18 Xueqing Road, Haidian District, Beijing, 100000 Patentee after: Beijing Special Medical Internet Biotechnology Co.,Ltd. Address before: 504, 5th Floor, Building 3, Fuhai Center, Daliushu, Haidian District, Beijing, 100080 Patentee before: Beijing Ebany Biological Medicine Technology Co.,Ltd. |
|
TR01 | Transfer of patent right |